Journal
CARDIOVASCULAR RESEARCH
Volume 117, Issue 5, Pages 1274-1283Publisher
OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvaa257
Keywords
Interleukin-23 receptor; Adaptive immunity; Immune therapy
Categories
Funding
- Canadian Institutes of Health Research (CIHR) First Pilot Foundation Grant [143348]
- Canada Research Chair (CRC) on Hypertension and Vascular Research by the CRC Government of Canada/CIHR Program
- Canada Fund for Innovation
Ask authors/readers for more resources
Hypertension is partially mediated by immune mechanisms, with IL-23 and IL-17 playing important roles. The IL-23/IL-17 axis has not been a major therapeutic target for hypertension treatment, but shows potential for targeting therapy.
Current knowledge suggests that hypertension is in part mediated by immune mechanisms. Both interleukin (IL)-23 and IL-17 are up-regulated in several experimental hypertensive rodent models, as well as in hypertensive humans in observational studies. Recent preclinical studies have shown that either IL-23 or IL-17A treatment induce blood pressure elevation. However, the IL-23/IL-17 axis has not been a major therapeutic target in hypertension, unlike in other autoimmune diseases. In this review, we summarize current knowledge on the role of these cytokines in immune mechanisms contributing to hypertension, and discuss the potential of IL-23/IL-17-targeted therapy for treatment of hypertension. [GRAPHICS] .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
